The abstract is read at the publisher; the summary is JClub's.
In 12 adults with non-diabetic proteinuric CKD, dietary sodium restriction (6.3 g salt/day) enhances the kidney effects of the selective ETA antagonist BQ123, unlike habitual intake.
- Why it matters: ERAs may treat proteinuric CKD, but it is unclear whether dietary sodium intake changes their kidney efficacy, leaving a practical adherence question unanswered.
- What they did: In a randomized, double-blind, placebo-controlled crossover study, participants received intravenous BQ123 or placebo during two 14-day diets, then had systemic and kidney hemodynamics and proteinuria measured.
- The result: BQ123 similarly reduced systolic blood pressure by about 12–14 mmHg and increased kidney blood flow by about 320–335 mL/min under both diets, but reduced GFR by about 5 mL/min/1.73 m², effective filtration fraction by about 1.5%, and proteinuria by about 300 μg/min only with sodium restriction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.